NEULANDLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.5
| Stock Code | NEULANDLAB | Market Cap | 19,249 Cr. | Current Price | 15,003 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 108 | Book Value | 1,257 ₹ | Dividend Yield | 0.08 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,879 ₹ | DMA 200 | 13,975 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 61.0 | MACD | 472 | Volume | 28,184 | Avg Vol 1Wk | 24,983 |
| Low price | 10,578 ₹ | High price | 19,748 ₹ | PEG Ratio | 2.28 | Debt to equity | 0.16 |
| 52w Index | 48.2 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 30.1 |
📊 Analysis: NEULANDLAB shows limited intraday potential. Current price (₹15,003) is above DMA 50 (₹13,879) and DMA 200 (₹13,975), confirming short-term strength. RSI at 61.0 indicates moderate bullish momentum, while MACD (472) supports positive bias. Volume (28K) is slightly above the 1-week average (25K), showing stable participation. However, PAT declined sharply (₹96.5 Cr → ₹40.4 Cr), raising caution. Valuation remains stretched with P/E (108 vs industry 30.1) and PEG ratio (2.28), limiting upside potential.
💹 Optimal Buy Price: ₹14,950–15,050 if sustained above VWAP with strong volume.
🎯 Profit Exit Levels: ₹15,200 (near resistance) and ₹15,500–15,800 (upper breakout zone).
🛑 Stop-Loss: ₹14,700 (below intraday support).
⏱️ If Already Holding: Consider booking profits near ₹15,200–15,800 if RSI approaches 65 or momentum slows. Exit if price breaks below ₹14,700 with rising sell pressure.
Positive
- Price trading above DMA 50 and DMA 200 confirms bullish bias.
- EPS of ₹139 provides valuation support.
- DII holding increased (+1.12%), showing domestic confidence.
- Moderate debt-to-equity ratio (0.16) ensures manageable leverage.
Limitation
- High P/E (108) compared to industry (30.1) indicates overvaluation.
- PEG ratio (2.28) suggests stretched valuations relative to growth.
- Quarterly PAT declined sharply (₹96.5 Cr → ₹40.4 Cr).
- FII holding reduced (-0.44%), showing weaker foreign sentiment.
- Dividend yield at 0.08% is negligible.
Company Negative News
- Sharp decline in quarterly profits raises earnings concerns.
- Reduced foreign institutional investor interest highlights caution.
Company Positive News
- Strong domestic institutional inflows (+1.12%) reflect confidence in long-term prospects.
- Price momentum supported by technicals above DMA levels.
- EPS strength provides valuation support despite earnings volatility.
Industry
- Industry P/E at 30.1 is much lower than NEULANDLAB’s 108, suggesting premium valuation risk.
- Pharma sector remains resilient with long-term demand drivers despite earnings volatility.
Conclusion
⚖️ NEULANDLAB offers limited intraday trading potential with strong technical momentum but suffers from stretched valuations and weak earnings. Suitable only for cautious trades above ₹14,950 with profit targets near ₹15,200–15,800 and strict stop-loss at ₹14,700. Momentum indicators suggest caution as RSI is already in moderately overbought territory.